

Patient organization funding

Novartis is committed to open dialogue and transparent exchange of information with patient organizations, as detailed in our [Commitment to Patients and Caregivers](#). Patient organizations are key partners in our decision-making throughout the medicine lifecycle. We believe that incorporating the patient perspectives in our decision-making can help to develop better medicines for patients.

Novartis engages with patient organizations in recognition of their unique expertise, experience, and perspectives. We fully respect their independence and integrity. Patient organizations are neither required nor encouraged to promote or endorse Novartis products and services. We do not initiate or drive the creation of new patient organizations and strive not to be the sole funder of any patient organization.

When engaging patient organization representatives, Novartis compensates them for their time and expenses according to local laws and regulations. Compensation is based on a fair market value (FMV) basis, following an established process and methodology. We believe patient organization representatives should receive fair remuneration for the services or consultancy they provide, based on their experience, expertise, and time. Committing to FMV – based payment is essential to build trust with the patient community and to strengthen our approach to patient engagement in a transparent, fair, and consistent manner.

Novartis discloses monetary and non-monetary support to patient organizations around the globe by June 30 each year, in compliance with the [EFPIA Code](#) and other industry codes such as the [PhRMA Principles on Interactions with Patient Organizations](#) to support our commitment to ethical and transparent relationships with patient organizations.

[Download the 2025 report \(525 KB\)](#) [Download the 2024 report \(734 KB\)](#) [Download the 2023 report \(707 KB\)](#)
[Read Novartis Position on Collaborating with Patient Organizations \(32 KB\)](#) [Global Patient Organization Methodological Note 2025 \(170 KB\)](#)

Source URL: <https://www.novartis.com/investors/reporting-and-transparency-hub/patient-organization-funding>

List of links present in page

1. <https://www.novartis.com/investors/reporting-and-transparency-hub/patient-organization-funding>
2. <https://www.novartis.com/patients-and-caregivers/novartis-commitment-patients-and-caregivers>
3. <https://www.efpia.eu/relationships-code/the-efpia-code/>
4. <http://phrma.org/resources/phrma-principles-on-interactions-with-patient-organizations>
5. https://www.novartis.com/sites/novartis_com/files/patient-organization-funding-report-2025.pdf
6. https://www.novartis.com/sites/novartis_com/files/patient-organization-funding-report-2024.pdf
7. https://www.novartis.com/sites/novartis_com/files/patient-organization-funding-report-2023.pdf
8. https://www.novartis.com/sites/novartis_com/files/novartis-position-on-collaborating-with-patient-organizations.pdf
9. https://www.novartis.com/sites/novartis_com/files/methodological-note-for-patient-organizations-2025.pdf